cyrilzakka/clinical-trials huggingface dataset:
Changing Eating Behavior Using Cognitive Training

Obesity is a global health problem. New and more efficient interventions are needed to overcome this disease. This randomized clinical trial aims to evaluate the effectiveness of changing eating behavior using cognitive training. These types of interventions have the role of creating new routines (unconsciously processed), in terms of healthy eating behaviors.

This is a randomized clinical trial with three groups. Participants will be found through social media announcements. The active interventions of cognitive training will be delivered at two groups: one group will receive through hypnosis and the other will receive through food inhibition training (a GO NO GO task). The control group will receive a simple GO NO GO task as an active placebo. The trial will be exclusively online and it consists of five sessions. Participants will complete their tasks on four Zoom sessions. Cognitive, emotional and behavioral data will be taken at four times: before the intervention starts, in the middle (after two sessions), at the end and at two follow up moments: one month and six months after the trial ends.

Eligibility Criteria:
Inclusion Criteria:

* Adults
* Persons who like high-calorie foods (self-report food preferences)
* Persons who have a medium to high score at the self-report daily snacking
* BMI\>25

Exclusion Criteria:

* Enrolled in a weight loss program
* Under 18 years
* Health problems that can affect weight loss
* Persons with clinical problems such as diabetes, cardiovascular disease, mental problems, persons who take medicines that can affect weight loss
Study Measuring Total Plasma Ropivacaine Levels During Continuous Peripheral Nerve Catheter Infusion

The purpose of the study is to measure the blood levels of the medicine called ropivacaine (local anesthetic) used to manage pain. Ropivacaine is a widely used medication and is not the subject of this study, but the investigators are studying how much of the drug can be found in the patient's blood, known as the blood level, of this medicine. Too much ropivacaine in a patient's blood can lead to local anesthetic toxicity. Once the nerve catheter is removed, local anesthetic toxicity is no longer a potential problem. However, there is little data on what ropivacaine blood levels are after having the catheter in for a long period of time(up to one month).


Eligibility Criteria:
Inclusion Criteria:

* Males and females 18 years and older, capable of providing informed consent indicating awareness of the investigational nature of the study, in keeping with institutional policy
* Written informed consent must be obtained from each patient prior to entering the study
* Patients must be scheduled to receive a continuous peripheral nerve catheter

Exclusion Criteria:

* Refusal to have serial blood drawn
* Contraindication for a continuous peripheral nerve catheter (allergy to local anesthetic, infection at site of injection, elevated coagulation times (international normalized ratio (INR)\>1.5, partial thromboplastin time (PTT)\>38; these values are drawn as part of routine standard of care and those values will be checked prior to initial catheter insertion), therapeutic dosing of anticoagulation medication, moderate to severe head injury and moderate to severe traumatic brain injury
* Patients with a hematocrit \< 20. Complete Blood Counts (CBCs) are drawn as part of routine standard of care and will be followed by the Acute Pain Service. Although the CBCs and ropivacaine blood draws will not always coincide, we will always check the last hematocrit obtained prior to our blood draw
* Severe liver or renal disease (values greater than two times normal range)
Three-month Clinical Evaluation of DSiHy Daily Disposable Silicone Hydrogel Contact Lenses

The purpose of this study is to evaluate the clinical performance of two daily disposable silicone hydrogel contact lenses. One of these lenses, the 'test' lens is an investigational product. This means that it has not yet been approved for commercial use and is not available for sale. The other lens (control) is a commercially available contact lens.

The results of this study will be analysed to determine how the 'test' lens compares with the 'control' lens. The control lens has been chosen because it is a market leader and is well tried and tested.

Participants who are in this study will need to have healthy eyes, except for the need to correct their eyesight. Up to 90 people who are aged 20 years or older will be considered for participation in this study. The study is designed to be approximately 3 months long.


Eligibility Criteria:
Inclusion Criteria:

* Be aged 20 years or more.
* Sign written informed consent.
* Be a currently adapted soft contact lens wearer (i.e. be wearing lenses at least 1 month prior to enrolment).
* Contact lens sphere requirement between -1.00 to -6.00 D (inclusive).
* Refractive astigmatism (if present) less than or equal to 0.75 D in both eyes.
* Be correctable by sphero-cylindrical refraction to 6/7.5 (+0.10 logMAR 0.8 decimal) or better in each eye.
* Require visual correction in both eyes (monovision allowed, no monofit.

Exclusion Criteria:

* Require toric or multifocal contact lenses.
* Concurrent ocular medication.
* Using systemic or topical medications that will in the investigator's opinion affect ocular physiology or contact lens performance.
* Any systemic illness affecting contact lens wear or the medical treatment of which would affect vision or successful lens wear (including diabetes).
* Clinically significant (≥Grade 2) corneal staining, corneal edema, corneal vascularization, tarsal abnormalities, bulbar hyperemia, limbal hyperemia, or any other abnormality of the cornea that would contraindicate contact lens wear.
* History of herpetic keratitis.
* Pathological dry eye.
* Aphakia or amblyopia.
* History of refractive surgery, keratoconus or other corneal irregularity.
* Pregnancy, lactating or planning a pregnancy at the time of enrolment.
* Participation in any concurrent clinical trial or within the last 30 days.
Caregiver Protocol for Remotely Improving, Monitoring, and Extending Quality of Life

The purpose of this study is to test an intervention to improve health promoting behaviors in family caregivers of patients receiving cancer therapy


Eligibility Criteria:
Inclusion Criteria:

* Eligible family caregivers will be:
* An unpaid family member or friend who provides assistance and support with healthcare of a non-institutionalized patient receiving some form of treatment for stage III or IV colorectal cancer at Moffitt Cancer Center
* Age 18+ years
* English or Spanish speaking
* Able to complete questionnaires and engage in short discussions with coaches
* Able to identify a primary care medical provider
* Willing/able to use a mobile device provided by the study team or their own their device.

Exclusion Criteria:

* Participants who do not meet the study inclusion criteria
Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease

The purpose of this trial is to evaluate whether, in Intravenous Immunoglobulin-naïve or refractory patients diagnosed with active Kawasaki disease, administration of canakinumab controls fever and acute phase reactants.


Eligibility Criteria:
Key Inclusion Criteria:

-Active Kawasaki disease defined as:

* fever ≥38.5°C for ≥5 days
* four out of five of the following criteria: (i) conjunctival injection, (ii) oral mucous membrane changes, (e.g., injected pharynx, or strawberry tongue), (iii) erythema of hands or feet, (iv) polymorphous rash, (v) cervical lymphadenopathy

Key Exclusion Criteria:

Patients fulfilling any of the following criteria are not eligible for inclusion in this study:

* Previous Kawasaki Disease diagnosis, refractory and/or incomplete Kawasaki disease (for IVIG-naïve patients, Cohort 1)
* Patients who had fever for longer than a week (for Intravenous Immunoglobulin-naïve patients, Cohort 1), or longer than 14 days (for Intravenous Immunoglobulin-refractory patients, Cohort 2)
* History of hypersensitivity to any of the study drugs or to drugs or similar chemical classes or excipients (e.g. citric acid and anhydrous sodium chloride disodium edetate dehydrate polysorbate 80; sodium hydroxide; water for injections)

Other protocol-defined inclusion/exclusion may apply.
High-flow Nasal Cannula Flow Rates, Severe Bronchiolitis

Objective: The investigators aimed to compare the heated humidified high-ﬂow nasal cannula (HHHFNC) flow rate of 1-L/kg/min (1L) with 2-L/kg/min (2L) in patients with severe bronchiolitis presenting to the pediatric emergency department.

Study design: The investigators performed a study in which all patients were allocated to receive these two flow rates. The primary outcome was admitted as treatment failure, which was defined as a clinical escalation in respiratory status. Secondary outcomes covered a decrease of respiratory rate (RR), heart rate (HR), the clinical respiratory score (CRS), rise of peripheral capillary oxygen saturation (SpO2) and rates of weaning, intubation and intensive care unit (ICU) admission.

Keywords: Bronchiolitis, Emergency department, High-flow nasal cannula, Flow rate


Eligibility Criteria:
Inclusion Criteria:

* Clinical diagnosis of severe bronchiolitis
* Must be less than 24 months
* Must have presented to the emergency department

Exclusion Criteria:

* Immediate invasive ventilation and/or intensive care unit admission
* Congenital heart disease,
* Chronic lung disease
* Neuromuscular disease
* Netabolic disease
* Craniofacial anomalies
* Immunocompromised
* Bacterial pneumonia
* Pneumothorax
* Nasal trauma
Acute Lung Injury After Cardiac Surgery: Pathogenesis

The purpose of the present study is to visualize the inflammatory response and coagulation disorders during cardiac surgery in order to identify possible predictors for acute lung injury postoperatively.

Acute lung injury after cardiac surgery is a common complication. The pathophysiology is complex and still not fully elucidate. No specific biomarkers are identified and the diagnosis is solely based on impaired oxygenation.

The purpose of the present study is to identify biomarkers of inflammation and coagulation in blood withdrawn simultaneous from the pulmonary artery and the left atrium during surgery and up to 20 hours after weaning from cardiopulmonary bypass.

Eligibility Criteria:
Inclusion Criteria:

* Elective surgery
* CABG
* In treatment with statins

Exclusion Criteria:

* Acute surgery
* Valve replacement
* In treatment with immunodepressive drugs
EYTO (European Youth Tackling Obesity): A Randomized Controlled Trial in Catalonia (Spain)

Our hypothesis is that healthy lifestyles improvement by an intervention designed according 8 social marketing Benchmark criteria, can reduce overweight or obesity implemented by adolescents on their colleges.

The general aim of EYTO program is to improve health and well-being among adolescents who live in low socioeconomically communities, through an intervention study designed by selected adolescents with the inclusion of social marketing Benchmark criteria.

5 adolescent coordinators (of intervention high-schools) will be trained by experts in social marketing and health promotion. This 5 selected adolescent as coordinators who will be in charge of the design of an 8 social marketing criteria intervention to implement their peers´ lifestyles.

The program has over two academic years. The participants will be followed for the duration of 2 academic years, an expected of up to 16 months.

Eligibility Criteria:
Inclusion Criteria:

* Informed consent signed by parents and/or guardians.
* Adolescents between 13 and 17 years old.

Exclusion Criteria:

- The lack of one or more inclusion criteria.
Evaluation of the Cosmetic Outcomes of Totally Endoscopic Cardiac Surgery

Totally endoscopic cardiac surgery (TECS) is considered to have aesthetic advantages over conventional median sternotomy due to the smaller incisions. Most research regarding TECS focuses on clinical outcomes instead of cosmetic consequences. Following surgery, postoperative scarring is unavoidable and may negatively affect the patient's physical and emotional well-being. Therefore, this study aims to investigate the cosmesis after TECS.

Totally endoscopic cardiac surgery (TECS) is considered to have aesthetic advantages over conventional median sternotomy due to the smaller incisions. Most research regarding TECS focuses on clinical outcomes instead of cosmetic consequences. Following surgery, postoperative scarring is unavoidable and may negatively affect the patient's physical and emotional well-being. One previous study compared median sternotomy cardiac surgery and TECS in terms of the long-term cosmetic appearance of postoperative scars. They concluded that scars were considered more satisfactory, less painful, and itchy in the TECS group in the Chinese population. To our knowledge, this is the only study published regarding cosmetic consequences after TECS. Therefore, this study aims to investigate the cosmesis after TECS.

Eligibility Criteria:
Inclusion Criteria:

* Patients older than 18 years old
* Patients who can give their informed consent
* Patients who speak Dutch or French

Exclusion Criteria:

* Patients that previously underwent cardiac surgery
* Patients that will undergo a combination of cardiac surgeries
Study on Use of Omega-3 Fatty Acids to Improve Outcomes in Individuals With Sickle Cell Disease

Sickle cell disease (SCD) is associated with significant morbidity and mortality. Pain and many adverse outcomes occurring in sickle cell disease are inflammatory driven. Recent data has shown that gut dysbiosis is present in individuals with sickle cell disease. Gut dysbiosis has been linked to inflammation in certain diseases. Omega -3-fatty acids (fish oil) has been shown to improve pain outcomes in individuals with sickle cell disease, but its acceptance is variable. The aim of this study is to determine if a plant-based omega-3-fatty acids will be more acceptable and also improve outcomes in individuals with sickle cell disease

Sickle cell disease (SCD) is associated with significant morbidity and mortality. Pain and many adverse outcomes occurring in sickle cell disease are inflammatory driven. Recent data has shown that gut dysbiosis is present in individuals with sickle cell disease. Gut dysbiosis has been linked to inflammation in certain diseases. Omega -3-fatty acids (fish oil) has been shown to improve pain outcomes in individuals with sickle cell disease, but its acceptance is variable. The aim of this study is to determine if a plant-based omega-3-fatty acids will be more acceptable and also improve outcomes in individuals with sickle cell disease.

Children aged 5-18 years will be randomized to receive a diet rich in omega-3-fatty acids versus a regular diet for 12 weeks after which there will be a cross over of arms after a 4-week wash out period. We will compare outcomes (including patient reported pain outcomes and improvement in inflammation markers) while on the omega-3 fatty acid rich diet.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of sickle cell anemia HbSS or HbSB0 thal at steady state
* Age 5-18 years old

Exclusion Criteria:

* Age less than 5 years
* Age \> 18 years old
* Chronic transfusion therapy
* Known to be pregnant
* Breastfeeding mothers
* Current use of antibiotics
* Use of pre or probiotic supplements
* PPI therapy
* Known allergy to FS
Clinical Outcomes of EUS-guided Biliary Drainage Using Partially or Fully Covered Metallic Stents

Although endoscopic retrograde cholangiopancreatography (ERCP) is almost always successful in patients with malignant biliary obstruction, selective biliary cannulation fails in some cases and conventional ERCP may not be possible in patients with tumor invasion of the duodenum or major papilla, surgically altered anatomy (e.g., Roux-en-Y anastomosis), or complex hilar biliary strictures. In such cases, percutaneous transhepatic biliary drainage (PTBD) is an useful alternative. However, PTBD had various complications and the presence of an external drainage catheter would also have a cosmetic problem related to the external drainage and an adverse impact on quality of life (QOL) of terminally ill patients.

Since endoscopic ultrasound-guided bile duct puncture was described in 1996, sporadic case reports of EUS-guided biliary drainage (EUS-BD) suggested that it was a feasible and effective alternative in patients with failed conventional ERCP stenting. The potential benefits of EUS-BD include one-stage procedure in ERCP unit, and internal drainage for avoiding long-term external drainage in cases where external PTBD drainage catheters cannot be internalized, thus significantly improving the QOL of terminally ill patients, and possibly lower morbidity than PTBD or surgery.

Up to date, only a few case series of EUS-BD with small numbers of patients have been published, and known the feasibility and safety in terms of the incidence of procedure-related clinical outcomes.

We investigated the efficacy and safety of EUS-BD using partially covered (hybrid) metallic stent with a dedicated introducer for EUS-BD, or fully covered antimigration metallic stents in malignant biliary obstruction after failed conventional ERCP as a prospective multicenter study.

Eligibility Criteria:
Inclusion Criteria:

* malignant biliary obstruction
* Inoperable state
* age \> 18 yrs
* failed primary ERCP

Exclusion Criteria:

* uncontrolled coagulopathy
* refuse to this study enrollment
Gastroesophageal Reflux Disease in Azerbaijan

To evaluate the prevalence of Gastroesophageal reflux disease in Azerbaijan. It is intended to evaluate the prevalence of the disease in the regions as well as the capital by cluster sampling ,ethitology and to compare the outcomes depending on the geographical location.

It is an observational, nationwide study. The GERD questionnaire (1994) requested from Mayo clinic, was received and validated. The questionnaire was translated by 3 individuals from english to azeri and back trasnlated by 3 native english speakers.

Power analysis was performed. The research was presented for the approval to Ethical Committee of Azerbaijan Medical University.

Prior to the actual study, a pilot study with smaller number of participants was performed and the results were evaluated.

Cluster sampling methodology was provided by the statistical department of Azerbaijan Medical University.

110 employees were hired for using a survey in different regions of Azerbaijan. Written consent was obtained from every person evaluated. Statistical ananlysis was performed.

Eligibility Criteria:
Inclusion Criteria:

* Age: 18-80
* Both genders
* Hearburn
* Belching
* Regurgitation

Exclusion Criteria:

* protom pomp inhibitor use
* antibiotic use in the last 4 weeks
* upper GI surgery
Evaluation of Chitosan Scaffold and Mineral Trioxide Aggregate Pulpotomy in Mature Permanent Molars With Irreversible Pulpitis

The aim of this study is to evaluate the clinical and radiographic outcomes of Chitosan scaffold and Mineral trioxide aggregate (MTA) when used as pulpotomy agents in mature permanent teeth with irreversible pulpitis.

Thirty permanent mandibular molars of patients with signs and symptoms of irreversible pulpitis will be selected. They will be randomly allocated into two groups, Group 1(Chitosan scaffold/ MTA pulp dressing materials), Group 2 (MTA pulp dressing material). A single visit full pulpotomy procedure will be carried out. Chitosan scaffold and / or MTA will be used as the pulp dressing materials. The teeth will be then restored with base of Glass ionomer cement followed by composite restoration.

Eligibility Criteria:
Inclusion Criteria:

* Participants free from any systemic disease.
* Deep caries in a permanent lower molar with mature roots.
* Probing pocket depth and mobility within normal limits.
* No signs of pulpal necrosis including sinus tract or swelling.
* Vital bleeding pulp tissue should be present in all canals after complete pulpotomy.
* The tooth is restorable.
* Clinical diagnosis of symptomatic irreversible pulpitis based on subjective and objective examinations:

  * Subjective examination: Patients complaining of intermittent or spontaneous pain or pain exacerbated by dramatic temperature changes especially to cold stimuli and lasting for a few seconds to several hours.
  * Objective examination:

    * Clinical examination: Teeth that will experience immediate, excruciatingly painful sensation as soon as the cold stimulus is placed on and which may last for a while even after the removal of the stimulus.
    * Radiographic examination: Preoperative radiographs will be taken using a paralleling device.
    * The periapical index developed by Orstavik et al. (1986)(35) will be used to score cases with periapical rarefaction during diagnosis and follow-up periods. It consists of five categories:

      1. Normal periapical structures.
      2. Small changes in bone structures.
      3. Change in bone structure with mineral loss.
      4. Periodontitis with well-defined radiolucent area.
      5. Severe periodontitis with exacerbating features. Score 1 and 2 are considered healthy, score 3-5 are considered diseased
    * The teeth that will be included should have score 1 or 2.

Exclusion Criteria:

* Negative response to cold testing.
* No pulp exposure after caries excavation.
* Bleeding could not be controlled in 10 minutes after 2.5% NaOCl
* Absence of bleeding from any of the canals.
* Teeth with radiographic signs of internal resorption.
* Pulpal calcifications.
* Participants with stainless-steel wires and brackets.
The Neuroprotection Effect of Dexmedetomidine

The brain protection effect of dexmedetomidine has been approved in several studies.

Basically, the anti-inflammatory effects and reducing catecholamines are thought to be a main role of the protection effect. In many studies reported the advantage of dexmedetomidine as a substitution of other sedative drugs for anesthesia.

The anesthesia of intra-cranial aneurysmal clipping operation commonly use intravenous anesthetic agents combined with inhalation anesthesia for neuroprotection, and mostly propofol is used.

The aim of this study is to examine the effects of dexmedetomidine on serum inflammatory markers and research the hemodynamic stability of dexmedetomidine compared to propofol in aneurysmal clipping operation.


Eligibility Criteria:
Inclusion Criteria:

* ASA class I,II patient needs operation of intracranial aneurysmal clipping without SAH

Exclusion Criteria:

* Any history of neurologic disease, dementia
* Allergic history of propofol or dexmedetomidine